Prophylactic use of VFS in patients with coronary artery disease in the perioperative coronary artery bypass grafting
Plechev, V.V.; Zagidullin, S.Z.; Iunusov, V.M.; Zubareva, I.G.; Nikolaeva, I.E.
Kardiologiia 53(8): 34-39
2013
ISSN/ISBN: 0022-9040 PMID: 24087998 Document Number: 666043
Tachyarrhythmias (TA) - dangerous postoperative complications of coronary artery bypass grafting, threatening the lives of patients and found, according to different authors, in 13-40% of cases. VFS - an antiarrhythmic drug that belongs to a class 1C, is effective in the treatment and prevention of a variety of cardiac arrhythmias. The aim of the work was to study the clinical efficacy of VFS CHD patients with a history of tachyarrhythmias during the perioperative period of coronary bypass surgery, as well as its comparison with other antiarrhythmic drug (amiodarone). Clinical efficacy was evaluated in 218 patients with coronary heart disease at baseline with a history of tachyarrhythmia (paroxysmal atrial fibrillation or premature ventricular high grade (IV and V class on classification of Lown B. and Wolf M. in the modification of Ryan M.). Shown that the VFS is more effective than amiodarone, both in paroxysmal atrial fibrillation and ventricular arrhythmias when high gradation.